| Q35192912 | Analgesia in patients with ESRD: a review of available evidence |
| Q34474045 | Analgesic agents. Pharmacology and application in critical care |
| Q53689504 | Analgesics in patients with hepatic impairment: pharmacology and clinical implications. |
| Q78104668 | Continuous subcutaneous infusion of morphine vs. hydromorphone: a controlled trial |
| Q35039129 | Demographics, assessment and management of pain in the elderly |
| Q39816897 | Effect of hydromorphone on ventilation in palliative care patients with dyspnea |
| Q48406950 | Hydromorphone-3-glucuronide: biochemical synthesis and preliminary pharmacological evaluation |
| Q37744893 | Implications of opioid analgesia for medically complicated patients |
| Q43898840 | LC-MS-MS analysis of hydromorphone and hydromorphone metabolites with application to a pharmacokinetic study in the male Sprague-Dawley rat. |
| Q37390742 | Mitigating the risk of opioid abuse through a balanced undergraduate pain medicine curriculum |
| Q28250437 | Opioid metabolism |
| Q37120711 | Options for treating postherpetic neuralgia in the medically complicated patient |
| Q55405502 | Pain Management in Pediatric Chronic Kidney Disease. |
| Q35163526 | Pain in terminally ill patients: guidelines for pharmacological management |
| Q33997294 | Palliative care and end-of-life issues |
| Q40872524 | Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients |
| Q34418203 | Recent advances in the use of opioids for cancer pain |
| Q44346373 | Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration: treatment strategies |
| Q37053718 | Update on prescription extended-release opioids and appropriate patient selection |